Oruka Therapeutics, Inc. (ORKA) stock
Close on Nov 12, 2026Market cap $6.95BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $6.95B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.81
- Dividend yield
- –
- Free cash flow yield
- -1.78%
Fundamentals
- Net income
- -$152.57M
- Free cash flow
- -$123.86M
Trading
- Previous close
- $107.17
- Open
- $105.10
- Day's range
- $101.50 – $107.01
- Volume
- 1,141,884
- Average volume (20 days)
- 1,033,539
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 0.50
- 52-week range
- $25.23 – $115.52
- RSI (14 days)
- 64.1
- Volatility (1 year)
- 69.3%
- Relative volume
- 1.24×
- WACC
- 7.4%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ORKA | S&P 500 | Difference | ORKA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +30.7% | -2.7% | +33.4 pts | ||
| 3 months | -2.2% | -1.7% | −0.5 pts | ||
| Year to date | +246.4% | +11.9% | +234.5 pts | ||
| 1 year | +271.0% | +12.0% | +259.0 pts | ||
| 3 years | +807.3% | +78.2% | +729.1 pts | +108.6% | +21.2% |
| 5 years | +558.6% | +73.2% | +485.3 pts | +45.8% | +11.6% |
| 10 years | -61.5% | +309.6% | −371.2 pts | -9.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Oruka Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Update
- Update
About Oruka Therapeutics
Pharmaceutical Preparations
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapies for chronic skin and inflammatory conditions. Its development pipeline targets validated biological pathways to treat diseases such as psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The company's lead investigational drug candidates include ORKA-001, an extended half-life antibody targeting interleukin-23p19, and ORKA-002, an extended half-life antibody targeting interleukin-17A and interleukin-17F. These therapeutics are designed to serve patients suffering from autoimmune and inflammatory disorders.
Company profile, executives and historyOruka Therapeutics stock: common questions
What is Oruka Therapeutics's stock price?
ORKA closed at $104.99 on Nov 12, 2026, down 2.03% on the day. Over the past 52 weeks it traded between $25.23 and $115.52.
What is Oruka Therapeutics's market cap?
Oruka Therapeutics was worth $6.95B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does Oruka Therapeutics pay a dividend?
No. Oruka Therapeutics has not paid a cash dividend over the last twelve months.
How has ORKA stock performed over the past year?
Including dividends, ORKA returned +271.0% over the past year, against +12.0% for the S&P 500.
How many ORKA shares are sold short?
6M shares were sold short at the latest FINRA report, 18.67% of the float, or 7.1 days of average trading volume.
Who are Oruka Therapeutics's competitors?
Companies most similar to Oruka Therapeutics by business, industry and size include EVMN, MLTX, AVTX, JBIO, UPB.
See a number that looks wrong?